Some patients taking SKYCLARYS in the clinical trial had an increase in liver enzymes, an increase in B-type natriuretic peptide (BNP, a protein that tells how well your heart is working), and changes in cholesterol levels.
Because of this, it is recommended that your healthcare provider check your liver function before starting treatment, for the first 3 months of treatment, and periodically throughout your treatment. Your healthcare provider will also check BNP levels and cholesterol levels before starting treatment with SKYCLARYS and will monitor you for changes in these areas periodically throughout your treatment.
Most common side effects in the clinical trial were considered “transient,” meaning they typically lasted less than 35 days
These tables show how long 51 patients taking SKYCLARYS and 52 patients taking placebo experienced some of the most common side effects reported in the clinical trial.
Data shown include side effects reported in greater than or equal to 20% of trial participants after 48 weeks.* They do not include any side effects that patients may have experienced if they continued taking SKYCLARYS after the trial ended. You should be aware that side effects can occur or reoccur at any point while taking SKYCLARYS.
The “median” length of time is different than the “average” length of time. A median is the middle value in a set of data, which means exactly half of the people experienced the side effect for less time, and half of the people experienced the side effect for more time. While the median divides the data set in half, quartiles divide it into quarters. Quartile 1 is the point at which one-quarter (25%) of people experienced the side effect for less time. Quartile 3 is the point at which three-quarters (75%) of people experienced the side effect for less time.
*Safety data was collected through the follow-up visit at week 52.
ALT=alanine aminotransferase; AST=aspartate
aminotransferase.